


Mifobate

Chemical Properties

CAS No. :	76541-72-5
Formula:	C ₁₁ H ₁₇ ClO ₇ P ₂
Molecular Weight:	358.65
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Mifobate (SR-202) is a potent and specific antagonist of PPAR γ , exhibiting antiobesity, antidiabetic, and antiatherosclerotic effects[1].
Targets(IC50)	PPAR
In vitro	SR-202 is a new synthetic PPAR γ antagonist,, which inhibits both TZD-stimulated recruitment of the coactivator steroid receptor coactivator-1 and TZD-induced transcriptional activity of the receptor.?In cell culture, SR-202 efficiently antagonizes hormone- and TZD-induced adipocyte differentiation[1].
In vivo	In vivo, decreasing PPAR γ activity, either by treatment with SR-202 or by invalidation of one allele of the PPAR γ gene, leads to a reduction of both high fat diet-induced adipocyte hypertrophy and insulin resistance.?These effects are accompanied by a smaller size of the adipocytes and a reduction of TNF α and leptin secretion.?Treatment with SR-202 also dramatically improves insulin sensitivity in the diabetic ob/ob mice[1].

Solubility Information

Solubility	H ₂ O: 35.87 mg/mL (100.01 mM),Sonication and heating are recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.7882 mL	13.9412 mL	27.8823 mL
5 mM	0.5576 mL	2.7882 mL	5.5765 mL
10 mM	0.2788 mL	1.3941 mL	2.7882 mL
50 mM	0.0558 mL	0.2788 mL	0.5576 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Rieusset J, et al. A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity. *Mol Endocrinol*. 2002 Nov;16(11):2628-44.

Doggrell S. Do peroxisome proliferation receptor-gamma antagonists have clinical potential as combined antiobesity and antidiabetic drugs? *Expert Opin on Investigational Drugs*, 2003, 12(4):713-716.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481